[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337307-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-337307-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","scoping-review-of-anticancer-drug-utilization-in-lung-cancer-patients-at-the-end-of-life","Scoping review of anticancer drug utilization in lung cancer patients at the end of life","","Scoping review examining end-of-life anticancer drug use in lung cancer patients, a setting defined by high mortality and substantial symptom burden. The review investigates treatment patterns and how methodological choices shape observed utilization, aiming to improve appropriateness of cancer care. Comprehensive Medline and Embase searches identified 68 publications, detailing timing, disease condition, regimens, treatment types, and end-of-life periods. Results show wide variation and highlight potential overtreatment, underscoring the need for standardized methods.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/scoping-review-of-anticancer-drug-utilization-in-lung-cancer-patients-at-the-end-of-life/337307/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/scoping-review-of-anticancer-drug-utilization-in-lung-cancer-patients-at-the-end-of-life/337307.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this scoping review?","Question",{"text":63,"@type":64},"To deepen understanding of end-of-life anticancer drug use in lung cancer patients and clarify treatment patterns that affect appropriateness of cancer care.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the literature searched and selected?",{"text":68,"@type":64},"Comprehensive searches were conducted in Medline and Embase to find articles describing anticancer drug utilization at the end of life in lung cancer patients.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the review find about the number and characteristics of studies?",{"text":72,"@type":64},"It identified 68 publications and characterized studies by timing, disease condition, treatment regimen and type, and features of treatment, showing that utilization frequency varies across end-of-life periods.",{"name":74,"@type":61,"acceptedAnswer":75},"Why does the review emphasize standardizing research methods?",{"text":76,"@type":64},"Methodological inconsistencies create challenges for evaluation and comparisons, and the review notes a notable proportion of patients experiencing potential overtreatment.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},337307,1790207228,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},"Research & Report",30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Clinical and Translational Oncology (2025) 27:1980–1993  \n[https://doi.org/10.1007/s12094-024-03711-1](https://doi.org/10.1007/s12094-024-03711-1)  \nScoping review of anticancer drug utilization in lung cancer patients at the end of life  \nEndre Szigethy1,2 · Mohammed Merzah2,3,4 · Ivan Sola5 · Gerard Urrútia5 · Xavier Bonfill5  \nReceived: 3 March 2024 / Accepted: 28 August 2024 / Published online: 5 October 2024 © The Author(s) 2024  \nAbstract  \nPurpose This scoping review aims to deepen the understanding of end-of-life anticancer drug use in lung cancer patients, a disease marked by high mortality and symptom burden. Insight into unique end-of-life treatment patterns is crucial for improving the appropriateness of cancer care for these patients.  \nMethods Comprehensive searches were carried out in Medline and Embase to find articles on the utilization of anticancer drugs in the end of life of lung cancer patients.  \nResults We identified 68 publications, highlighting the methodological characteristics of studies including the timing of the research, disease condition, treatment regimen, type of treatment, and features of the treatment. We outlined the frequency of anticancer drug use throughout different end-of-life periods.  \nConclusion This review provides a comprehensive overview of primary studies exploring end-of-life treatments in lung cancer patients. Methodological inconsistencies pose many challenges, revealing a notable proportion of patients experiencing potential overtreatment, warranting more standardized research methods for robust evaluations.  \nKeywords Lung cancer · Anticancer agents · Terminal care · Medical overuse  \nIntroduction  \nThe application of anticancer drugs during end-of-life care represents a complex and debated issue, with significant variability observed in their utilization across diverse methodological contexts [1–3] . The administration of anticancer drugs near the end-of-the-life period is progressively  \n* Endre Szigethy [Endre.Szigethy@autonoma.cat](Endre.Szigethy@autonoma.cat)  \n1 PhD Programme in Biomedical Research Methodology and Public Health, Universitat Autònoma de Barcelona, Barcelona, Spain  \n2 Epidy Kft, Csúcs Utca 9, Debrecen 4034, Hungary  \n3 Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary  \n4 Technical Institute of Karbala, Al Furat Al Awsat Technical University, Kufa, Iraq  \n5 Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), CIBER Epidemiologíay Salud Pública (CIBERESP), Universitat Autònoma de Barcelona, Barcelona, Spain  \nprevalent, especially among patients with solid tumors such as lung, breast, and colorectal cancer [1, 4–9] .  \nThe real merits of these treatments in terms of survival enhancement and life quality improvement are often ambiguous, and in certain instances, they may be overshadowed by potential harms, including adverse reactions and treatment burdens [1, 7 , 10–12] . An expanding corpus of literature posits that the decision to employ anticancer drugs during the end-of-life period is shaped by a broad spectrum of factors, such as patient preferences, physician’s attitudes, healthcare system characteristics [13–16], or cancer types [17] .  \nThe substantial financial burden of these therapies raises ethical and economic concerns, leading to increased advocacy for palliative care, which prioritizes comfort and quality of life (QoL) over curative efforts [2, 12, 18] . Palliative care, emphasizing symptom management and psychological support, is increasingly recognized as a more suitable approach for end of life, focusing on dignity, patient preferences, and enhancing QoL rather than merely prolonging life. This shift reflects the growing understanding that QoLis a crucial measure of effective end-of-life care [19, 20] .  \nIn discussing the use of anticancer drugs during endof-life care, it is important to define what is meant by“end-of-life” In this context, the ","cbCaiag05Pv1YdvF","https://ap.wps.com/l/cbCaiag05Pv1YdvF","pdf",757289,14,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the purpose of this scoping review?\",\"answer\":\"To deepen understanding of end-of-life anticancer drug use in lung cancer patients and clarify treatment patterns that affect appropriateness of cancer care.\"},{\"question\":\"How was the literature searched and selected?\",\"answer\":\"Comprehensive searches were conducted in Medline and Embase to find articles describing anticancer drug utilization at the end of life in lung cancer patients.\"},{\"question\":\"What did the review find about the number and characteristics of studies?\",\"answer\":\"It identified 68 publications and characterized studies by timing, disease condition, treatment regimen and type, and features of treatment, showing that utilization frequency varies across end-of-life periods.\"},{\"question\":\"Why does the review emphasize standardizing research methods?\",\"answer\":\"Methodological inconsistencies create challenges for evaluation and comparisons, and the review notes a notable proportion of patients experiencing potential overtreatment.\"}]","Scoping review of anticancer drug utilization in lung cancer patients at the end of life | PDF",1790018543,35]